2007
Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer
Liedtke C, Mazouni C, Hess K, Tordai A, André F, Symmans W, Gonzalez-Angulo A, Green M, Hortobagyi G, Pusztai L. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer. Journal Of Clinical Oncology 2007, 25: 10519-10519. DOI: 10.1200/jco.2007.25.18_suppl.10519.Peer-Reviewed Original ResearchTriple-negative statusHigh nuclear gradeTriple-negative breast cancerTriple-negative tumorsLong-term survivalBreast cancerNuclear gradeNeoadjuvant chemotherapyOverall survivalNegative tumorsIndependent unfavorable prognostic factorHER2/neu expressionMD Anderson Cancer CenterComplete pathological responseProgesterone receptor expressionInvasive breast cancerPositive nodal statusTriple-negative groupUnfavorable prognostic factorAnderson Cancer CenterBasal-like subtypeRetrospective comparative analysisNegative control groupNeoadjuvant trialsRemainder patientsIdentification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients
Wu S, Chasalow S, Lee H, Xu L, Paul B, Mokliatchouk O, Symmans W, Zerba K, Pusztai L, Clark E. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients. Journal Of Clinical Oncology 2007, 25: 2525-2525. DOI: 10.1200/jco.2007.25.18_suppl.2525.Peer-Reviewed Original ResearchBreast cancer patientsER patientsCancer patientsPredictive markerClinical trialsPaclitaxel activityER-negative breast cancer patientsComplete pathological responseER-negative patientsTaxane-containing regimensTaxane-containing therapyExpression levelsIxabepilone treatmentPatient selectionBC patientsPathological responseIxabepilonePatientsTherapeutic valueProtein 3SiRNA studiesDifferential markersROC curveTrialsCandidate markers
2004
Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer
Pusztai L, Krishnamurti S, Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer. Cancer Investigation 2004, 22: 248-256. PMID: 15199607, DOI: 10.1081/cnv-120030213.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarrier ProteinsCell DeathChemotherapy, AdjuvantDNA-Binding ProteinsDoxorubicinFemaleHumansImmunohistochemistryMiddle AgedNeoadjuvant TherapyPredictive Value of TestsPrognosisProto-Oncogene Proteins c-bcl-2Transcription FactorsTreatment OutcomeConceptsComplete pathological responsePathological responseBcl-2 expressionNeoplastic cellsBcl-2Breast cancerTissue specimensSubsequent pathological responsesAdvanced breast cancerBAG-1Breast epithelial cellsBAG-1 expressionExploratory pilot studyPrechemotherapy specimensNeoadjuvant chemotherapyClinical responseResidual tumorCytotoxic therapyPosttreatment specimensAnti-apoptotic proteinsPreoperative doxorubicinChemotherapyCytoplasmic stainingIndividual tumorsBreast tissue